Mak LY, et al. - In a total of 459 hepatitis B e antigen (HBeAg)-negative patients (224 untreated, 235 treated with nucleos(t)ide analogues [NAs]), researchers examined how liver fibrosis, as determined by liver stiffness measurements, changes in chronic hepatitis B patients over 10 years. Fibrosis progression was observed in correlation to an absence of treatment with NAs, metabolic syndrome, and hepatic steatosis. They observed a positive correlation of liver stiffness decline with the time following HBsAg seroclearance. Patients with cirrhosis-related complications/hepatocellular carcinoma had higher median liver stiffness both at baseline (14.0 vs 6 kPa) and after 10 years (9.1 vs 4.9 kPa) vs those without. Time-dependent decline in liver stiffness was observed in patients with HBsAg seroclearance.